The Israeli-American company Oramed, based in Jerusalem, is currently developing a new corona vaccine. Instead of being injected, it should simply be swallowed, reports the Jerusalem Post. The oral vaccination is currently still being tested on animals, but the trials will start on humans as early as April, Oramed boss Nadav Kidron told the newspaper.
The oral vaccine is said to have several advantages: In contrast to the vaccines from Biontech / Pfizer and Moderna, the oral vaccine is said to provide better protection against virus variants. This is because the tablet targets three corona structural proteins instead of the single spike protein like the current vaccines. On the other hand, there tend to be fewer side effects with drugs taken orally, explains Kidron.
Should be able to be stored at room temperature
The production of the vaccination tablet is also less expensive: the yeast-based pill can be produced with less expenditure of time and money. As far as the transport and storage of the oral vaccination is concerned, it should also be less complicated here. The tablet can namely be shipped at refrigerator temperature and stored at room temperature: “This will facilitate the global distribution of the vaccination,” Kidron continues.
Further advantages of the oral vaccination: No staff is required. That would mean: no appointment chaos, no logistics problems and no additional training for the nursing staff.
Human clinical trials from April
According to the company, tests on animals have shown that oral vaccination is able to stimulate the formation of important corona antibodies. This is necessary to ensure protection against a virus infection. In the coming quarter, the vaccine will be tested in humans as part of a clinical trial.
In the initial phase, the pill is to be tested on a few test subjects for tolerance and immune response. Only when this has been passed should the oral vaccination be checked for its effectiveness. However, it will be a few more months before the study gets to that point.
The clinical studies could be carried out in Europe, the USA, Israel or Mexico, said Kidron. In Africa, in particular, where there is a lack of infrastructure and staff to administer conventional vaccines, the tablet could be important. The company therefore hopes to be able to test the vaccine in Africa as well. (une)
Published: 23.03.2021, 2:22 p.m.
Last updated: 23.03.2021, 2:34 pm